scholarly journals The state of the eyes in patients with end-stage chronic renal failure depending on the method of renal replacement therapy

2012 ◽  
Vol 93 (2) ◽  
pp. 238-241
Author(s):  
L K Moshetova ◽  
O V Shmarina ◽  
R V Storozhev ◽  
Yu A Anisimov ◽  
I V Dmitriev ◽  
...  
Keyword(s):  
Renal Failure ◽  
Visual Acuity ◽  
Peritoneal Dialysis ◽  
Chronic Renal Failure ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
The State ◽  
Metastatic Calcification ◽  
Arterial Blood ◽  
End Stage

Aim. To assess the state of the organ of vision in patients with end-stage chronic renal failure, who are on renal replacement therapy with hemodialysis and peritoneal dialysis. Methods. Examined were 35 patients with end-stage chronic renal failure. The first group consisted of 20 patients receiving renal replacement therapy with hemodialysis, the second group consisted of 15 patients treated with continuous ambulatory peritoneal dialysis. In addition to the standard ophthalmologic techniques (visual acuity, tonography, perimetry, biomicroscopy and ophthalmoscopy) conducted were optical coherence tomography and photographic imaging of the retina. The following data were also taken into account: arterial blood pressure, blood hemoglobin, creatinine and urea levels and indicators of phosphorus-calcium metabolism. Results. Regardless of the method of blood dialysis of all patients had decreased corrected visual acuity. In the patients of the first group it was 0.88±0.13, in the second group - 0.71±0.19. Also in both groups revealed was a concentric narrowing of the visual fields by 5-10%. Conclusion. In patients on hemodialysis, revealed was more severe course of retinopathy; in patients on continuous peritoneal dialysis, the most frequently encountered was swelling of the retina, metastatic calcification manifested to a lesser extent.

scholarly journals Successful Renal Replacement Therapy for a Patient with Severe Hemophilia after Surgical Treatment of Intracranial Hemorrhage and Hydrocephalus

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Noriko Kato ◽  
Masami Chin-Kanasaki ◽  
Yuki Tanaka ◽  
Mako Yasuda ◽  
Yukiyo Yokomaku ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Hemophilia A ◽  
Severe Hemophilia ◽  
End Stage Renal Failure ◽  
Japanese Male ◽  
Old Japanese ◽  
End Stage

A 21-year-old Japanese male with severe hemophilia A was developed end-stage renal failure. He was placed on combination therapy with peritoneal dialysis (PD) and hemodialysis (HD). Eight months later, he developed a hypertensive cerebral hemorrhage. After emergency surgery, he was managed with PD without HD to avoid cerebral edema. One month later, his renal replacement therapy was switched to HD (three times a week) from PD, since a ventriculoperitoneal shunt catheter was placed to treat his hydrocephalus. HD could be performed safety without anticoagulant agents on condition that factor VIII is given after every HD.

scholarly journals Incidence of end stage renal disease on renal replacement therapy in Nepal

1970 ◽  
Vol 7 (3) ◽  
pp. 301-305 ◽  
Author(s):  
R Hada ◽  
S Khakurel ◽  
RK Agrawal ◽  
RK Kafle ◽  
SB Bajracharya ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Female Ratio ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End stage renal disease patients are treated with dialysis in Nepal. But there is no renal registry to indicate the burden of disease in the country. Objectives: The objective of this study is to find out the incidence of ESRD on renal replacement therapy and their out come. Materials and methods: It is a retrospective analysis (audit) of all ESRD patients who had received dialysis inside Nepal and had under gone transplantation from 1990 to 1999. The haemodialysis (HD) registry, HD patients file, intermittent peritoneal dialysis (IPD) registry of Bir Hospital, Shree Birendra Hospital, Tribhuwan University Teaching hospital and National Kidney Center were reviewed. Acute renal failure and acute on chronic renal failure were excluded and the demographic profile, dialysis session, dialysis duration and outcome of all ESRD patients were computed. One patient was counted only once in spite of attending more than one center for dialysis. SPSS package was used for analysis. Results: Total number of 1393 ESRD patients received renal replacement therapy (RRT) in the decade. Mean age of patients were 46.7 ± 16.7 with 70% of ESRD were between 20-60 years age with male: female ratio of 1.8:1. Initial mode of RRT was IPD in 58.2%, HD in 41.7% and pre-emptive transplantation in 0.1% patients. Records of 189 patients could not be found and out of remaining 1208 patients, 85.8% received dialysis for < 3 months, 6% received dialysis for more than a year and 9.5% had undergone kidney transplantation. The incidence of ESRD had increased gradually with 3.4 per million populations (pmp) in 1990 to 11.89 pmp in 1999 with an average annual incidence of 6 pmp and only 0.31% of expected ESRD patients received RRT. Conclusion: The incidence of ESRD is increasing but majority discontinue or die within 3 months. Dialysis centers needs to be expanded to different parts of country and prospective studies have to be carried out to find out of cause of ESRD and to institute preventive measures.Key words: End stage renal disease; Renal replacement therapy; Haemodialysis; Intermittent peritoneal dialysis; Incidence of end stage renal disease; Nepal. DOI: 10.3126/kumj.v7i3.2742 Kathmandu University Medical Journal (2009) Vol.7, No.3 Issue 27, 302-305

scholarly journals The cost of dialysis renal replacement therapy for end-stage renal disease patients in Ukraine

2019 ◽  
pp. 4-10
Author(s):  
M. Kolesnyk ◽  
L. Liksunova ◽  
T. Selezneva ◽  
T. Maistrenko
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
The State ◽  
State Budget ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Expenses for the treatment of end-stage renal disease (ESRD) patients with dialysis renal replacement therapy (DRRT) during the 2018 year constituted 2 billion 922 million 460 thousand UAH. Reimbursement from the state budget constituted 1 billion 44 million 800 thousand UAH. Expendable materials were the main component of DRRT. The share of the expendable materials price from total cost for hemodialysis and hemodiafiltration constituted 66%, for continuous ambulatory peritoneal dialysis and automatic peritoneal dialysis was 86.3% and 92.2%, respectively. The results of the investigation can be used for the development of a diversification model (state budget – local budgets – other sources) of financial expenses for the provision of dialysis treatment in ESRD patients as a part of the state program (strategy) health care finance and service delivery.

HUBUNGAN KEPATUHAN PASIEN MENJALANI TERAPI HEMODIALISA DENGAN TINGKAT DEPRESI PASIEN GAGAL GINJAL KRONIK DI KLINIK RASYIDA MEDAN TAHUN 2015

2016 ◽  
Vol 1 (1) ◽  
pp. 39-46
Author(s):  
Jagentar P Pane
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Chi Square ◽  
Cross Sectional ◽  
Measuring Devices ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Relationship

Chronic renal failure or end stage renal disease (ESRD) is a progressive disorder of renal function and irreversible regardless of the cause. Renal replacement therapy consists of hemodialysis, peritoneal dialysis and kidney transplantation. Hemodialysis therapy is a renal replacement therapy is the most widely performed and the numbers from year to year continues to increase. Dialysis.Goal:The purpose of this study was to determine the relationship between adherence to undergo hemodialysis therapy with the level of depression in patients with chronic renal failure Rasyida Clinic Medan Year 2015.Chronic renal failure or end stage renal disease (ESRD) is a progressive disorder of renal function and irreversible regardless of the cause. Renal replacement therapy consists of hemodialysis, peritoneal dialysis and kidney transplantation. Hemodialysis therapy is a renal replacement therapy is the most widely performed and the numbers from year to year continues to increase. Dialysis.Goal:The purpose of this study was to determine the relationship between adherence to undergo hemodialysis therapy with the level of depression in patients with chronic renal failure Rasyida Clinic Medan Year 2015.Method:The study design with Analitik descriptive, cross-sectional method, sampling is done with purposive sampling. Samples are 69 respondents. Compliance questionnaire measuring devices and depression. Data analysis was performed using Chi-square analysis.Result: value of p = 0.023 (p <0.05). The figure indicates that there is a significant relationship between adherence variables undergo hemodialysis therapy with levels of depression patients with chronic renal failure. Based on the data obtained by processing the majority of respondents did not obey as many as 34 people (49.3%) and respondents were obedient as many as 35 people (50.7%) and respondents were depressed as many as 21 people (30.4%) and respondents who are not depressed as much as 48 people (69.6%).Method:The study design with Analitik descriptive, cross-sectional method, sampling is done with purposive sampling. Samples are 69 respondents. Compliance questionnaire measuring devices and depression. Data analysis was performed using Chi-square analysis.Result: value of p = 0.023 (p <0.05). The figure indicates that there is a significant relationship between adherence variables undergo hemodialysis therapy with levels of depression patients with chronic renal failure. Based on the data obtained by processing the majority of respondents did not obey as many as 34 people (49.3%) and respondents were obedient as many as 35 people (50.7%) and respondents were depressed as many as 21 people (30.4%) and respondents who are not depressed as much as 48 people (69.6%).

Continuous Hemodiafiltration in Children

PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 819-823
Author(s):  
Nancy A. Bishof ◽  
Thomas R. Welch ◽  
C. Frederic Strife ◽  
Frederick C. Ryckman
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Peritoneal Dialysis ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Effective Means ◽  
Tumor Lysis Syndrome ◽  
Intermittent Hemodialysis ◽  
Tumor Lysis ◽  
Continuous Arteriovenous Hemofiltration

Continuous arteriovenous hemofiltration is a form of renal replacement therapy whereby small molecular weight solutes and water are removed from the blood via convection, alleviating fluid overload and, to a degree, azotemia. It has been used in many adults and several children. However, in patients with multisystem organ dysfunction and acute renal failure, continuous arteriovenous hemofiltration alone may not be sufficient for control of azotemia; intermittent hemodialysis or peritoneal dialysis may be undesirable in such unstable patients. Recently, the technique of continuous arteriovenous hemodiafiltration has been used in many severely ill adults. We have used continuous arteriovenous hemodiafiltration in four patients at Children's Hospital Medical Center. Patient 1 suffered perinatal asphyxia and oliguria while on extracorporeal membrane oxygenation. Patients 2 and 4 both had Burkitt lymphoma and tumor lysis syndrome. Patient 3 had septic shock several months after a bone marrow transplant. All had acute renal failure and contraindications to hemodialysis or peritoneal dialysis. A blood pump was used in three of the four patients, while spontaneous arterial flow was adequate in one. Continuous arteriovenous hemodiafiltration was performed for varying lengths of time, from 11 hours to 7 days. No patient had worsening of cardiovascular status or required increased pressor support during continuous arteriovenous hemodiafiltration. The two survivors (patients 2 and 4) eventually recovered normal renal function. Continuous arteriovenous hemodiafiltration is a safe and effective means of renal replacement therapy in the critically ill child. It may be ideal for control of the metabolic and electrolyte abnormalities of the tumor lysis syndrome.

Reactivation of Systemic Lupus in three Patients Undergoing CAPD

1986 ◽  
Vol 6 (1) ◽  
pp. 6-9 ◽  
Author(s):  
George G. Wu ◽  
D.R. Gelbart ◽  
James A. Hasbargen ◽  
Robert Inman ◽  
Peter McNamee ◽  
...  
Keyword(s):  
Renal Failure ◽  
Peritoneal Dialysis ◽  
Immune System ◽  
Chronic Renal Failure ◽  
Lupus Nephritis ◽  
End Stage Renal Disease ◽  
Systemic Lupus ◽  
Immunological Changes ◽  
Stage Renal Disease ◽  
End Stage

Generally patients with end-stage renal disease (ESRD) due to lupus nephritis, have minimal extrarenal disease activity <Juring hemodialysis. This may be related to immunological changes secondary to chronic renal failure or the dialysis procedure itself, or both. This paper describes three patients with lupus nephritis undergoing continuous ambulatory peritoneal dialysis (CAPD) in whom we observed reactivation of SLE, by both clinical and serological criteria. This may suggest that in patients undergoing CAPD the immune system is more nearly intact than in hemodialysis. These cases should heighten awareness that patients may suffer flare-ups of SLE during CAPD even long after the onset of renal failure.

scholarly journals Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration

2010 ◽  
Vol 54 (6) ◽  
pp. 2596-2602 ◽  
Author(s):  
Verena Hafner ◽  
David Czock ◽  
Jürgen Burhenne ◽  
Klaus-Dieter Riedel ◽  
Jürgen Bommer ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Half Life ◽  
Repeated Measures ◽  
High Flux ◽  
Polysulfone Membrane ◽  
End Stage Renal Failure ◽  
Beta Cyclodextrin ◽  
End Stage

ABSTRACT Sulfobutylether-beta-cyclodextrin (SBECD), a large cyclic oligosaccharide that is used to solubilize voriconazole (VRC) for intravenous administration, is eliminated mainly by renal excretion. The pharmacokinetics of SBECD and voriconazole in patients undergoing extracorporeal renal replacement therapies are not well defined. We performed a three-period randomized crossover study of 15 patients with end-stage renal failure during 6-hour treatment with Genius dialysis, standard hemodialysis, or hemodiafiltration using a high-flux polysulfone membrane. At the start of renal replacement therapy, the patients received a single 2-h infusion of voriconazole (4 mg per kg of body weight) solubilized with SBECD. SBECD, voriconazole, and voriconazole-N-oxide concentrations were quantified in plasma and dialysate samples by high-performance liquid chromatography (HPLC) and by HPLC coupled to tandem mass spectrometry (LC-MS-MS) and analyzed by noncompartmental methods. Nonparametric repeated-measures analysis of variance (ANOVA) was used to analyze differences between treatment phases. SBECD and voriconazole recoveries in dialysate samples were 67% and 10% of the administered doses. SBECD concentrations declined with a half-life ranging from 2.6 ± 0.6 h (Genius dialysis) to 2.4 ± 0.9 h (hemodialysis) and 2.0 ± 0.6 h (hemodiafiltration) (P < 0.01 for Genius dialysis versus hemodiafiltration). Prediction of steady-state conditions indicated that even with daily hemodialysis, SBECD will still exceed SBECD exposure of patients with normal renal function by a factor of 6.2. SBECD was effectively eliminated during 6 h of renal replacement therapy by all methods, using high-flux polysulfone membranes, whereas elimination of voriconazole was quantitatively insignificant. The SBECD half-life during renal replacement therapy was nearly normalized, but the average SBECD exposure during repeated administration is expected to be still increased.

Sign in / Sign up

Export Citation Format

Share Document